Olaparib是一种抗癌症药物,在治疗BRCA2突变的男子的生化复发性前列腺癌方面具有潜力。 Olaparib, an anti-cancer drug, shows potential in treating biochemically recurrent prostate cancer in men with BRCA2 mutations.

一项对JAMA肿瘤学的研究显示,olaparib是一种抗癌症药物,可以有效地治疗生物化学复发性前列腺癌,而无需对具有BRCA2等基因突变的男子进行荷尔蒙治疗。 A study in JAMA Oncology shows that olaparib, an anti-cancer drug, could be effective for treating biochemically recurrent prostate cancer without hormone therapy in men with mutations in genes like BRCA2. 在51名病人中,13名病人的PSA下降了50%,所有11名BRCA2突变的病人都显示了这一结果。 Out of 51 patients, 13 experienced a 50% PSA decrease, with all 11 patients with BRCA2 mutations showing this outcome. 该药物的安全情况与以前的报告一致,可以作为一种非激素治疗选择,避免荷尔蒙疗法的副作用。 The drug's safety profile was consistent with previous reports, and it may serve as a non-hormonal treatment option, avoiding hormonal therapy side effects.